NCT04617054

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

A Phase II, Multicenter, Open, Basket Study of AB-106 to Treat the Subjects With Local Progression or Systemic Metastasis Solid Tumors With NTRK Gene Fusion

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Nuvation Bio Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

AB-106 will be administered once a day. Each treatment cycle is defined as 21 days of continuous medication. Dosing will continue until any of the following conditions are met: disease progression, intolerable drug-related adverse events, researchers recommend discontinuation of treatment, withdrawal of informed consent, pregnancy during the study, use of other anti-tumor therapy, loss of follow-up, death and other causes, whichever occurs first. The study includes a screening period, treatment period, safety follow-up and long-term follow-up.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	AB-106	600mg QD for each subjects.

Timeline

• Start date: 2021-06-01
• Primary completion: 2024-12-06
• Completion: 2024-12-06
• First posted: 2020-11-05
• Last updated: 2026-01-21

Locations

1 site across 1 country: China